Jay Overholser
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
-
- Cancer, Hypoxia, and Metabolism
Papers in ⓘ
-
- Immunotherapy and Immune Responses 6
- Oncology 10
- HER2/EGFR in Cancer Research 5
- CAR-T cell therapy research 3
- Cancer Immunotherapy and Biomarkers 3
- Co-authors
- Philip E. Thorpe (3 shared papers)Victor Stastny (1 shared paper)John D. Minna (1 shared paper)Rolf A. Brekken (1 shared paper)Johannes Waltenberger (1 shared paper)Daniel J. Hicklin (3 shared papers)Pravin T. P. Kaumaya (8 shared papers)Harlan W. Waksal (2 shared papers)
- Journals
- OncoImmunology (4 papers)Cancer (2 papers)Clinical Cancer Research (1 paper)Frontiers in Oncology (1 paper)The Journal of Immunology (1 paper)
- Partner nations
- United StatesChina
In The Last Decade
Jay Overholser
16 papers receiving 739 citations
Peers
Comparison fields: 5 of 78
- Oncology 358
- Cancer Research 157
- Immunology 186
- Immunology and Allergy 48
- Molecular Biology 439
Countries citing papers authored by Jay Overholser
This map shows the geographic impact of Jay Overholser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Overholser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Overholser more than expected).
Fields of papers citing papers by Jay Overholser
This network shows the impact of papers produced by Jay Overholser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Overholser. The network helps show where Jay Overholser may publish in the future.
Co-authors
The 25 scholars most cited alongside Jay Overholser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. | 2000 | 269 |
| 2 | 2000 | 139 | |
| 3 | Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. | 2002 | 86 |
| 4 | 2019 | 54 | |
| 5 | 2022 | 50 | |
| 6 | 2013 | 37 | |
| 7 | 2020 | 26 | |
| 8 | 2014 | 24 | |
| 9 | 2022 | 21 | |
| 10 | 2015 | 17 | |
| 11 | 2022 | 16 | |
| 12 | 2000 | 8 | |
| 13 | 2014 | 8 | |
| 14 | 1995 | 7 | |
| 15 | 1994 | 4 | |
| 16 | 2023 | 1 |
About Jay Overholser
Jay Overholser is a scholar working on Immunology, Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology and Allergy, having authored 16 papers that have together received 767 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (8 papers), Immunotherapy and Immune Responses (6 papers), HER2/EGFR in Cancer Research (5 papers), Glycosylation and Glycoproteins Research (5 papers), Angiogenesis and VEGF in Cancer (3 papers), CAR-T cell therapy research (3 papers), vaccines and immunoinformatics approaches (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). The work is most often cited by research in Oncology (358 citations), Cancer Research (157 citations), Immunology (186 citations), Immunology and Allergy (48 citations) and Molecular Biology (439 citations). Jay Overholser has collaborated with scholars based in United States and China. Frequent co-authors include Philip E. Thorpe, Victor Stastny, John D. Minna, Rolf A. Brekken, Johannes Waltenberger, Daniel J. Hicklin, Pravin T. P. Kaumaya, Harlan W. Waksal, Marie Prewett and Andrea T. Hooper. Their work appears in journals such as OncoImmunology, Cancer, Clinical Cancer Research, Frontiers in Oncology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.